Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.424
G. Sarode, S. Sarode, Nikunj Maniyar, N. Sharma, Sujata Yerwadekar, S. Patil
{"title":"Recent trends in predictive biomarkers for determining malignant potential of oral potentially malignant disorders","authors":"G. Sarode, S. Sarode, Nikunj Maniyar, N. Sharma, Sujata Yerwadekar, S. Patil","doi":"10.4081/oncol.2019.424","DOIUrl":"https://doi.org/10.4081/oncol.2019.424","url":null,"abstract":"Despite of the tremendous advancements in the field of cancer prevention, detection and treatment, the overall prognosis of oral squamous cell carcinoma (OSCC) still remains poor. This can be partly imparted to the lack of early detection of oral potentially malignant disorders (OPMDs), especially those at a higher risk of progression into OSCC. Over years, various specific and non-specific markers have been introduced that could predict the malignant transformation of OPMDs; however detail information on these OPMD markers in a concise manner is lacking. Moreover, their use on daily clinical basis still remains questionable. With continuous research in the field of cytology and genomics, several contemporary biomarkers have been discovered that are not yet foregrounded and proved to be more promising than those used conventionally. Here, in the present paper, we overview several recently concluded predictive biomarkers with special emphasis on their role in molecular pathogenesis of OSCC transformation. These markers can be used for risk assessment of malignant transformation in patients with OPMDs as well as for prophylactic conciliation and fair management of the high-risk OPMD patient group.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.424","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42567484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.422
L. Mendoza
{"title":"Potential effect of probiotics in the treatment of breast cancer","authors":"L. Mendoza","doi":"10.4081/oncol.2019.422","DOIUrl":"https://doi.org/10.4081/oncol.2019.422","url":null,"abstract":"Breast cancer is one of the most important causes of cancerrelated morbidity and mortality in the world. Probiotics, as functional food, have the potential to act against breast cancer, as evidenced by cell-based and animal model experiments. Probiotic may be useful in prevention or treatment of breast cancer by modulating the gastrointestinal bacteria and the systemic immune system. However, large-scale clinical trials and intensive research are mandatory to confirm the in vitro and in vivo results and exploring the probiotics-related metabolic, immune, and molecular mechanisms in breast cancer. This current review summarizes the available data related to probiotics and their potential role in the treatment of breast cancer.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46073448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.440
Dileep Kumar Reddy Regalla, R. Jacob, A. Manne, R. Paluri
{"title":"Therapeutic options for ampullary carcinomas. A review","authors":"Dileep Kumar Reddy Regalla, R. Jacob, A. Manne, R. Paluri","doi":"10.4081/oncol.2019.440","DOIUrl":"https://doi.org/10.4081/oncol.2019.440","url":null,"abstract":"Ampullary Carcinoma arises from a histologically heterogeneous region where three different epithelia converge. Even though Ampullary Carcinoma has a superior prognosis compared to pancreatic and biliary ductal neoplasms, at least half of the patients turn up at an advanced stage that limits the treatment prospects. In addition to surgery for early-stage disease, several studies have shown that chemoradiotherapy confers additional benefits in the management of Ampullary Carcinoma. Analogously, chemotherapy plays a crucial role in treating advanced Ampullary Carcinoma with distant metastasis/recurrences. Although, stage of the disease, lymph node status, and histo-morphology are three critical prognostic variables, recently much attention is being placed on the genetic landscape of Ampullary Carcinoma. In this review, we have discussed various studies describing the role of chemoradiation and chemotherapy in the treatment of early and advanced stage Ampullary Carcinoma. Also, we have summarized the molecular landscape of Ampullary Carcinoma and the novel therapeutic strategies which could possibly target the genetic alterations involving the tumor cells.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42228429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.435
S. Alsagaby
{"title":"Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia","authors":"S. Alsagaby","doi":"10.4081/oncol.2019.435","DOIUrl":"https://doi.org/10.4081/oncol.2019.435","url":null,"abstract":"B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 18% of the afflicted patients during the first 5 years after diagnosis. Molecular heterogeneities of pediatric B-ALL play important roles as determinants of the therapy response. Therefore, many of these molecular abnormalities have an established prognostic value in the disease. The present review discusses the omics-based revelations from epigenomics, genomics, transcriptomics and proteomics about treatment failure in pediatric B-ALL. Next it highlights the promise of the molecular aberration-targeted therapy to improve the treatment outcomes.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.435","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43322093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.421
Faiza Naseer, M. Saleem
{"title":"Epigenetic modification in the expression of p73 p73 - epigenetic target for anticancer therapy","authors":"Faiza Naseer, M. Saleem","doi":"10.4081/oncol.2019.421","DOIUrl":"https://doi.org/10.4081/oncol.2019.421","url":null,"abstract":"A p73 is a new member of p53 family of transcription factor, having two types. First is TAp73, transcriptionally active and expressed via upstream promoter as a tumor suppressor and vital apoptotic inductor, it also has a key role in cell cycle arrest/differentiation and Second is ΔNp73 that is transcriptionally inactive and expressed via downstream regulator as oncogenes. Both types are expressed in various isoforms, which originate from alternative splicing events at the C-terminus. Upon DNA damage, posttranslational modifications cause conformational changes in various amino acid residues via induction or inhibition of various proteins, which are present in the structural domains of p73. These modifications may cause up- or down-regulation of p73 expression levels, as well as alters the transcriptional activity and/or stability of the protein. In this review, we have made an effort to assemble all existing data regarding the role of p73, its modification and after effects in cancer.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46806620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.430
Jacob S. Bowers, Stefanie R. Bailey, M. Rubinstein, C. Paulos, E. Camp
{"title":"Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy","authors":"Jacob S. Bowers, Stefanie R. Bailey, M. Rubinstein, C. Paulos, E. Camp","doi":"10.4081/oncol.2019.430","DOIUrl":"https://doi.org/10.4081/oncol.2019.430","url":null,"abstract":"Pancreatic adenocarcinoma (PDAC) remains a formidable disease that needs improved therapeutic strategies. Even though immunotherapy has revolutionized treatment for various solid tumor types, it remains largely ineffective in treating individuals with PDAC. This review describes how the application of genome-wide analysis is revitalizing the field of PDAC immunotherapy. Major themes include new insights into the body’s immune response to the cancer, and key immunosuppressive elements that blunt that antitumor immunity. In particular, new evidence indicates that T cell-based antitumor immunity against PDAC is more common, and more easily generated, than previously thought. However, equally common are an array of cellular and molecular defenses employed by the tumor against those T cells. These discoveries have changed how current immunotherapies are deployed and have directed development of novel strategies to better treat this disease. Thus, the impact of genomic analysis has been two-fold: both in demonstrating the heterogeneity of immune targets and defenses in this disease, as well as providing a powerful tool for designing and identifying personalized therapies that exploit each tumor’s unique phenotype. Such personalized treatment combinations may be the key to developing successful immunotherapies for pancreatic adenocarcinoma.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46867961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.408
A. Asnafi, M. Mohammadi, Hadi Rezaeeyan, Nader Davari, N. Saki
{"title":"Prognostic significance of mutated genes in megakaryocytic disorders","authors":"A. Asnafi, M. Mohammadi, Hadi Rezaeeyan, Nader Davari, N. Saki","doi":"10.4081/oncol.2019.408","DOIUrl":"https://doi.org/10.4081/oncol.2019.408","url":null,"abstract":"Megakaryopoiesis is a process during which platelets that play a major role in hemostasis are produced due to differentiation and maturation of megakaryocytic precursors. Several genes, including oncogenes and tumor suppressor genes, play a role in the regulation of this process. This study was conducted to investigate the oncogenes and tumor suppressor genes as well as their mutations during the megakaryopoiesis process, which can lead to megakaryocytic disorders. Relevant literature was identified by a PubMed search (1998-2019) of English language papers using the terms ‘Megakaryopoiesis’, ‘Mutation’, ‘oncogenes’, and ‘Tumor Suppressor’. According to investigations, several mutations occur in the genes implicated in megakaryopoiesis, which abnormally induce or inhibit megakaryocyte production, differentiation, and maturation, leading to platelet disorders. GATA-1 is one of the important genes in megakaryopoiesis and its mutations can be considered among the factors involved in the incidence of these disorders. Considering the essential role of these genes (such as GATA- 1) in megakaryopoiesis and the involvement of their mutations in platelet disorders, study and examination of these changes can be a positive step in the diagnosis and prognosis of these diseases.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.408","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45253034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology ReviewsPub Date : 2019-07-22DOI: 10.4081/oncol.2019.416
Amrallah A. Mohammed, Hanaa Rashied, F. M. Elsayed
{"title":"CDK4/6 inhibitors in advanced breast cancer, what is beyond?","authors":"Amrallah A. Mohammed, Hanaa Rashied, F. M. Elsayed","doi":"10.4081/oncol.2019.416","DOIUrl":"https://doi.org/10.4081/oncol.2019.416","url":null,"abstract":"Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.416","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43484784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Thrombocytopenia in solid tumors: Prognostic significance.","authors":"Majid Ghanavat, Mina Ebrahimi, Hassan Rafieemehr, Mahmood Maniati, Masumeh Maleki Behzad, Saeid Shahrabi","doi":"10.4081/oncol.2019.413","DOIUrl":"10.4081/oncol.2019.413","url":null,"abstract":"<p><p>Solid tumors are a heterogeneous group of malignancies that result from out-of-control proliferation of cells. Thrombocytopenia is a common complication among patients with solid tumors that predispose them to bleeding disorders. The aim of this review article is to investigate the underlying mechanisms of the risk and incidence of thrombocytopenia in solid tumors. It can be argued that thrombocytopenia is a poor prognostic factor in solid tumors that can result from several factors such as polymorphism and mutation in some transcription factors and cytokines involved in megakaryocytic maturation or from the adverse effects of treatment. Therefore, an understanding of the exact mechanism of thrombocytopenia pathogenesis in each stage of solid tumors can help in developing therapeutic strategies to decrease bleeding complications in these malignancies.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"413"},"PeriodicalIF":3.1,"publicationDate":"2019-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/00/onco-13-1-413.PMC6542370.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37061071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic significance of aberrant CD5 expression in B-cell leukemia.","authors":"Kaveh Jaseb, Daryush Purrahman, Saeid Shahrabi, Majid Ghanavat, Hadi Rezaeean, Najmaldin Saki","doi":"10.4081/oncol.2019.400","DOIUrl":"https://doi.org/10.4081/oncol.2019.400","url":null,"abstract":"<p><p>Aberrant expression of CD5 (as a T-cell marker) is seen in some leukemia and lymphoma of B lineage origin. Given that the signaling resulting from the expression of this marker plays an essential role in the development of leukemia and lymphoma, evaluating the expression of this marker is of paramount importance. Therefore, our goal in this study was to investigate the prognostic importance of CD5 expression in B-cell leukemia and lymphoma. We evaluate CD5 expression in normal and leukemic B-cells by identifying relevant literature through a PubMed search (1998-2018) of English language papers using the terms: '<i>CD5,' 'B-cell,' 'Leukemia</i>,' and <i>'Lymphoma.</i>' We are doing this thorough comparison of results from CD5 positive and negative cases to make a correct decision about prognostic importance of CD5 expression in these malignancies. In a number of B-cell malignancies, CD5 is expressed in varying degrees. Due to the different origins and characteristics of these malignancies, the results of CD5 expression evaluations are heterogeneous and impossible to generalize. However, CD5 expression is sometimes associated with clinicopathologic findings, more invasive clinical course, and even resistance to treatment (specifically in DLBCL) among CD5- positive patients, which appears to be a function of CD5 signaling and its downstream factors such as STAT3. Depending on the type of malignancy, CD5 expression is associated with good or bad prognosis, which can be used as an auxiliary prognostic factor to assess the clinical course of B-cell malignancies. Moreover, the difference in expression levels of CD5 in a variety of B-cell malignancies allows for differential diagnosis of these malignancies, which can be helpful when diagnosis is difficult.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"400"},"PeriodicalIF":3.6,"publicationDate":"2019-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.400","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37204652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}